The FDA’s Principal Investigator for 3D Printed Medical Devices is Looking for Industry Feedback and No One is Giving It to Him
Medical applications for 3D printing are a rapidly growing segment of the 3D printing industry, and the technology could radically alter the way that many medical issues are evaluated and treated. Applications as diverse as inexpensive, customized 3D printed prosthetic devices, patient-specific surgical implants, surgical pre-planning and even personalized medications all have the medical community changing the way that it thinks about healthcare. 3D printing technology could potentially lead us into an age of personalized medicine by allowing doctors, surgeons and pharmacists to tailor and fabricate medical devices and drugs for specific individuals, not create mass produced products for the average patient as they are now.
In the United States, before any 3D printed medical device can be marketed and sold it must gain approval from the Food and Drug Administration (FDA) where it needs to be evaluated for safety. Currently the process of evaluation for new 3D printed devices can be tricky and extremely time consuming for manufacturers. The primary reason is because the technology is so new that there are no specific standards in place that companies are expected to adhere to before submitting products for review. Traditionally manufactured medical devices already have these standards in place so companies have a very clear idea of how they need to be made, what tests they must pass and what materials can and cannot be used. Currently the FDA is in the process of writing these regulations for 3D printed devices, and in May they released a draft of their Technical Considerations for Additive Manufactured Devices to the public for review.
“Most of the specifications right now are on the basic materials, bio formats, descriptive terms. We’re trying to bring knowledge of FDA best practices, knowledge of our regulatory requirements to the additive manufacturing standard so we can help foster industry growth, by letting them know what they need to do, letting them have clarity in things like testing methods,” explained James Coburn, the principal investigator for the FDA’s Center for Devices and Radiological Health.
Having these guidelines in place will be a huge development for 3D printed medical devices, and will offer significant guidance to the developers and manufacturers of these products. When the draft is finalized, it will lay out a clear roadmap for companies submitting products for review and to give them the best chance possible of it being approved. It will also be a major validation for the viability of 3D printing technology in general, and will most likely lead to an uptick in the development of additively manufactured medical products and services. The FDA has already evaluated and cleared 85 3D printed medical devices and 1 3D printed prescription drug, and they are clearly motivated to clear more. In addition to the released draft laying out the potential guidelines that the FDA is considering putting in place, it also focuses on specific areas where they believe the technology will make the most impact.
“With patient-specific devices, there are a lot of areas where people have been thinking about doing this, but it’s been cost prohibitive or technologically prohibitive, and 3D printing has opened up a lot of those doors,” continued Coburn.
Among the devices that have already been cleared by the FDA are orthopedic implants that can be 3D printed to fit the patient’s body exactly and patient-specific surgical instruments that can be 3D printed to help doctors speed up the surgical process. These types of products were cleared using the federal agency’s current regulatory oversight over medical devices and drugs, which is not always the ideal method of evaluation. It is in both the medical community’s and the manufacturers’ best interest to have accurate and specific regulations in place both to ensure the products’ safety and to speed up the review process.
While all federal agency guidelines usually are released in draft form to the public simply for transparency’s sake, when it comes to 3D printed medical devices the need for specificity is vitally important. Because the technology is still considered emergent and evolving, the feedback and input from the industry that the FDA will be regulating is going to be invaluable to the final technical considerations. The FDA considered the draft their “initial thoughts” on the subject and have opened the document up for comment through August 8th, 2016. But according to The Hill so far they have only received 3 public comments since the draft was released in May.
I really can’t stress how important feedback from the 3D printing industry is to making sure that the FDA gets this right. Frankly, it is much easier to influence the rules before they are written than it is to change them after they have been written. The companies that manufacture 3D printed medical devices, implants and surgical tooling should be making the review of the draft a priority. After all, as Coburn notes “This only gets better with outside expertise”. You can learn more about how the FDA reviews 3D printed medical devices and follow the process of finalizing the draft of the eventual guidelines here. Discuss further in the FDA 3D Printing Regulations forum over at 3DPB.com.
You May Also Like
3D Printing News Briefs: July 2nd, 2019
We’re talking partnerships and materials in today’s 3D Printing News Briefs. The Alfa Romeo F1 team and Additive Industries are strengthening their technology partnership, while Beam-IT and SLM Solutions are...
Premium AEROTEC Partnering with Lockheed Martin to Search for 3D Printing Opportunities on the F-35
The Paris Air Show ended over a week ago, but event news from the 3D printing industry continues to fly in as we hear about more investment and partnership announcements. The...
New Balance and Formlabs Launch TripleCell 3D Printing Platform and Rebound Resin for Athletic Shoes
While I’m not much for recreational jogging these days, I’ll always remember my first real running shoes – a pair of dark gray Sauconys, which I got to pick out...
Carbon and Arkema’s Sartomer Subsidiary Partner to Increase Materials Performance & Digital Manufacturing Adoption
Four years ago, specialty chemical and advanced materials developer Arkema announced that it would increase its focus on 3D printing materials research; this was followed two years later by a major investment...
View our broad assortment of in house and third party products.